Decoy Therapeutics (NASDAQ:DCOY) Short Interest Update

Decoy Therapeutics (NASDAQ:DCOY) saw a large increase in short interest in the month of June. As of June 30th, there was short interest totaling 156,313 shares, an increase of 7,850.8% from the June 15th total of 1,966 shares. Based on an average trading volume of 1,217,647 shares, the short-interest ratio is currently 0.1 days. Currently, 29.9% of the shares of the company are short sold.

Decoy Therapeutics Price Performance

Shares of DCOY stock traded down $0.35 during trading on Friday, reaching $5.91. 18,981 shares of the company’s stock were exchanged, compared to its average volume of 678,565. Decoy Therapeutics has a twelve month low of $4.32 and a twelve month high of $415.80. The business has a fifty day moving average price of $6.42. The stock has a market capitalization of $3.13 million, a PE ratio of -0.06 and a beta of 0.59.

Decoy Therapeutics (NASDAQ:DCOY) last announced its quarterly earnings results on Friday, May 8th. The company reported ($4.18) earnings per share (EPS) for the quarter. Sell-side analysts anticipate that Decoy Therapeutics will post -12.97 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Decoy Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, June 12th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $30.00.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.